



(12) **United States Patent**  
**Sousa Martin et al.**

(10) **Patent No.:** **US 9,410,962 B2**  
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **DETERMINATION OF LEVELS OF IMMUNOGENIC GLUTEN PEPTIDES IN HUMAN SAMPLES**

(75) Inventors: **Carolina Sousa Martin**, Sevilla (ES);  
**Isabel Comino Montilla**, Sevilla (ES);  
**Ana Real Calderon**, Sevilla (ES);  
**Santiago Vivas Alegre**, Sevilla (ES);  
**Angel Cebolla Ramirez**, Sevilla (ES)

(73) Assignee: **Universidad De Sevilla**, Sevilla (ES)

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/977,247**

(22) PCT Filed: **Dec. 28, 2011**

(86) PCT No.: **PCT/ES2011/000379**

§ 371 (c)(1),  
(2), (4) Date: **Sep. 17, 2013**

(87) PCT Pub. No.: **WO2012/089868**

PCT Pub. Date: **Jul. 5, 2012**

(65) **Prior Publication Data**

US 2014/0178903 A1 Jun. 26, 2014

(30) **Foreign Application Priority Data**

Dec. 28, 2010 (ES) ..... 201001633

(51) **Int. Cl.**

**G01N 33/24** (2006.01)  
**G01N 33/68** (2006.01)  
**G01N 33/531** (2006.01)  
**G01N 33/53** (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC ..... **G01N 33/68** (2013.01); **G01N 33/5308**  
(2013.01); **G01N 2333/415** (2013.01); **G01N**  
**2800/065** (2013.01)

(58) **Field of Classification Search**

CPC ..... **A61B 10/0038**; **G01N 2333/415**;  
**G01N 2800/065**; **G01N 33/5091**; **G01N 33/68**;  
**G01N 2800/06**; **G01N 33/564**; **G01N 33/582**;  
**G01N 33/6893**; **G01N 33/5308**; **G01N 33/531**;  
**G01N 33/6854**; **G01N 2800/24**; **G01N 33/53**;  
**C07K 14/415**; **A61K 38/08**; **A61K 8/64**  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

4,208,479 A \* 6/1980 Zuk et al. .... 435/79  
7,563,864 B2 \* 7/2009 Marti et al. .... 530/324  
2006/0189540 A1 \* 8/2006 Khosla et al. .... 514/15

**OTHER PUBLICATIONS**

Catassi et al., (Am J Clin Nutr 2007;85:160-6).\*

Millipore Application Guide (2008, retrieved from URL:www.mil-lipore.com/publications.nsf/a73664f9f981af8c852569b9005b4ee/348ee7096d93729685256bf40066a40d/\$FILE/tb500en00.pdf).\*

Herbert Wieser. Chemistry of gluten proteins, Food Microbiology 24 (2007) pp. 115-119.

Alessio Fasano. Surprises from Celiac Disease, Scientific American, Aug. 2009, pp. 32-39.

Roger H. Erickson. Digestion and Absorption of Dietary Protein, Annual Review of Medicine 1990, 41, pp. 133-139.

Vadivel Ganapathy. Protein Digestion and Absorption, Physiology of the Gastrointestinal Tract, Fourth Edition, Academic Press, 2006, pp. 1667-1692.

Michael T. Bethune. Parallels between Pathogens and Gluten Peptides in Celiac Sprue, PLoS Pathogens, Feb. 2008, vol. 4, Issue 2, e34, pp. 1-16, www.plospathogens.org.

Bana Jabri. Tissue-mediated control of immunopathology in coeliac disease, Nature, Dec. 2009, vol. 9, pp. 858-870, www.nature.com/reviews/immunol.

Alessio Fasano. Celiac Disease, New England Journal of Medicine, 367; 25, Dec. 20, 2012, pp. 2419-2426.

Greetje J. Tack. The spectrum of celiac disease: epidemiology, clinical aspects and treatment, Nature Reviews, Gastroenterology & Hepatology, vol. 7, Apr. 2010, pp. 204-213.

Lu Shan. Structural Basis for Gluten Intolerance in Celiac Sprue, Science, vol. 297, Sep. 27, 2002, pp. 2275-2279.

Michael T. Bethune. Noninflammatory Gluten Peptide Analogs as Biomarkers for Celiac Sprue, Chem Biol. Aug. 28, 2009; 16(8): pp. 868-881. doi:10.1016/j.chembiol.2009.07.009.

Jason A. Tye-Din. Comprehensive, Quantitative Mapping of T Cell Epitopes in Gluten in Celiac Disease, Science Translational Medicine, vol. 2, Issue 41, 41ra51, Jul. 21, 2010, pp. 1-14.

Carolina Ciacci. Long-Term Follow-Up of Celiac Adults on Gluten-Free Diet: Prevalence and Correlates of Intestinal Damage, Digestion, 2002; 66: pp. 178-185.

Jocelyn A. Silvester. Long-term follow-up of individuals with celiac disease: An evaluation of current practice guidelines, Canadian Journal of Gastroenterology & Hepatology, vol. 21, No. 9, Sep. 2007, pp. 557-564.

*Primary Examiner* — Shafiqul Haq

*Assistant Examiner* — Carmencita M Belei

(74) *Attorney, Agent, or Firm* — McNees Wallace & Nurick LLC

(57) **ABSTRACT**

The present invention, fitted in the medical-clinical sector, shows a method for monitoring the ingestion of gluten by measuring protein/gluten peptides present in fecal samples with antibodies against immunogenic peptides resistant to gastrointestinal digestion. The presence or absence of said immunogenic peptides is controlled by immunological assays based on reactive antibodies against immunogenic gluten peptides that are resistant to proteolysis. These assays may be quantitative techniques as ELISAs, or qualitative as rapid immunochromatographic assays, immunoblots, etc. These measures may also be applied to verify compliance with the gluten-free diet, to improve diagnosis in cases of refractory or severe symptoms of celiac disease, in cases in which a gluten-free diet is supposedly being respected, or to clinical research on the effectiveness of enzymatic therapies related with prolamins detoxification.

**6 Claims, 4 Drawing Sheets**